Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Three key findings result from our study: (1) pwIIH treated with GLP-1-RAs lose significantly more weight than pwIIH electing for UCWM only, (2) treatment with GLP-1-RAs is associated with favorable headache outcomes, and (3) treatment with GLP-1-RAs is not associated with any severe adverse events in IIH, and thus presents a safe treatment option for weight management in pwIIH
Gastrointestinal effects also contribute to changing food preferences
Synergy Rx asks two condition multi-selects with a suicidal-thoughts checkbox and the cancer 5-year-remission threshold, but MTC and MEN2 family history are not asked anywhere in the visible flow a significant FDA-black-box gap
Demand for GLP-1 improves the capacity utilisation of fill-finish capabilities offered by CDMOs While GLP-1 manufacturers are investing significantly in the development of the drug, few have the capacity to complete filling and packaging in-house
The gut mycobiome in health, disease, and clinical applications in association with the gut bacterial microbiome assembly
